Literature DB >> 16042582

DNA damage hypersensitivity in cells lacking BRCA2: a review of in vitro and in vivo data.

T Hay1, A R Clarke.   

Abstract

Since the discovery of the tumour suppressor BRCA2 (encoded by breast-cancer susceptibility gene 2), cells lacking the fully functional protein have consistently been found to show increased sensitivity to a variety of DNA-damaging agents, particularly those that cross-link DNA. In this short review, we will bring together these findings and discuss them in the light of our recent in vivo data in the mouse small intestine, which suggests that deletion of cells lacking Brca2 is necessary to avoid the development of potentially tumorigenic clones in this tissue, a system that may be less effective in the mammary glands of humans with germline mutations in BRCA2.

Entities:  

Mesh:

Year:  2005        PMID: 16042582     DOI: 10.1042/BST0330715

Source DB:  PubMed          Journal:  Biochem Soc Trans        ISSN: 0300-5127            Impact factor:   5.407


  5 in total

1.  A new mutation of BRCA2 gene in an Italian healthy woman with familial breast cancer history.

Authors:  Maurizio Pisanò; Valeria Mezzolla; Maria Maddalena Galante; Giovanni Alemanno; Corrado Manca; Vito Lorusso; Antonio Malvasi; Andrea Tinelli
Journal:  Fam Cancer       Date:  2011-03       Impact factor: 2.375

2.  Double-strand break repair-independent role for BRCA2 in blocking stalled replication fork degradation by MRE11.

Authors:  Katharina Schlacher; Nicole Christ; Nicolas Siaud; Akinori Egashira; Hong Wu; Maria Jasin
Journal:  Cell       Date:  2011-05-13       Impact factor: 41.582

3.  Talazoparib in Patients with a Germline BRCA-Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA Trial.

Authors:  Sara A Hurvitz; Anthony Gonçalves; Hope S Rugo; Kyung-Hun Lee; Louis Fehrenbacher; Lida A Mina; Sami Diab; Joanne L Blum; Jayeta Chakrabarti; Mohamed Elmeliegy; Liza DeAnnuntis; Eric Gauthier; Akos Czibere; Iulia Cristina Tudor; Ruben G W Quek; Jennifer K Litton; Johannes Ettl
Journal:  Oncologist       Date:  2019-11-25

4.  Efficacy and safety of talazoparib in Japanese patients with germline BRCA-mutated locally advanced or metastatic breast cancer: results of the phase 1 dose-expansion study.

Authors:  Haruru Kotani; Norikazu Masuda; Toshinari Yamashita; Yoichi Naito; Tetsuhiko Taira; Kenichi Inoue; Masato Takahashi; Kan Yonemori; Shigeyuki Toyoizumi; Yuko Mori; Takashi Nagasawa; Natsuki Hori; Hiroji Iwata
Journal:  Breast Cancer       Date:  2022-07-30       Impact factor: 3.307

5.  Talazoparib in Patients with a Germline BRCA-Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA Trial.

Authors:  Sara A Hurvitz; Anthony Gonçalves; Hope S Rugo; Kyung-Hun Lee; Louis Fehrenbacher; Lida A Mina; Sami Diab; Joanne L Blum; Jayeta Chakrabarti; Mohamed Elmeliegy; Liza DeAnnuntis; Eric Gauthier; Akos Czibere; Iulia Cristina Tudor; Ruben G W Quek; Jennifer K Litton; Johannes Ettl
Journal:  Oncologist       Date:  2019-11-25
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.